Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2131)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (129)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (855)
  3. JNCI: Journal of the National Cancer Institute (492)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (140)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4676)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Long-term outcomes with nivolumab (nivo) vs docetaxel (doc) in patients (pts) with advanced (adv) NSCLC: CheckMate 017 and CheckMate 057 2-y update
    Meeting Abstract

    Barlesi, F.; Steins, M.; Horn, L.; Ready, N.; Felip, E.; Borghaei, H.; Spigel, D. R.; Arrieta, O.; Antonia, S. J.; Fayette, J.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumours
    Meeting Abstract

    Baselga, J.; Castan, J. C.; De Laurentiis, M.; Dieras, V.; Harbeck, N.; Hsu, J.; Jin, H.; Schimmoller, F.; Wilson, T. R.; Im, Y. H.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • A phase 1b study of abemaciclib, an inhibitor of CDK4 and CDK6, in combination with endocrine and HER2-targeted therapies for patients with metastatic breast cancer
    Meeting Abstract

    Beeram, M.; Tolaney, S. M.; Beck, J. T.; Dickler, M. N.; Conlin, A. K.; Dees, C.; Helsten, T. L.; Conkling, P. R.; Edenfield, W. J.; Richards, D. A.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Everolimus / pazopanib (E/P) benefits genomically selected patients (pts) with metastatic urothelial carcinoma (mUC)
    Meeting Abstract

    Bellmunt, J.; Mullane, S. A.; Jacobus, S.; Polacek, L.; Takeda, D. Y.; Harshman, L.; Choueiri, T.; Wagle, N.; Van Allen, E. M.; Kantoff, P.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • IMvigor210: Updated analyses of first-line (1L) atezolizumab (atezo) in cisplatin (cis)-ineligible locally advanced/metastatic urothelial carcinoma (mUC)
    Meeting Abstract

    Bellmunt, J.; Balar, A.; Galsky, M. D.; Loriot, Y.; Theodore, C.; Pulido, E. G.; Castellano, D.; Retz, M.; Niegisch, G.; Bracarda, S.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • A phase 2 study of the aurora kinase A inhibitor alisertib for patients with neuroendocrine prostate cancer (NEPC)
    Meeting Abstract

    Beltran, H.; Danila, D.; Montgomery, B.; Szmulewitz, R.; Vaishampayan, U.; Armstrong, A.; Stein, M.; Hoimes, C.; Pinski, J.; Scher, H.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Clinical characteristics and outcomes of patients with metastatic colorectal cancer (CRC) harboring NRAS mutations
    Meeting Abstract

    Braghiroli, M. I.; Chou, J. F.; Hechtman, J. F.; Capanu, M.; Cercek, A.; Yaeger, R.
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Molecular characterization of HER2-positive (HER2+) metastatic gastric and gastro-esophageal junction cancer patients (mGC): Identification of resistance mechanisms to trastuzumab-based therapy (TTZ)
    Meeting Abstract

    Alsina, M.; Hierro, C.; Sastre, J.; Guardeno, R.; Lopez, C.; Pineda, E.; Aranda, E.; Manzano, J. L.; Galan, M.; Longo, F.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Phase 1/2 study of the safety and clinical activity of durvalumab in patients with non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Antonia, S. J.; Brahmer, J. R.; Khleif, S.; Balmanoukian, A. S.; Ou, S. H. I.; Gutierrez, M.; Kim, D. W.; Kim, S. W.; Ahn, M. J.; Leach, J.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: Preliminary results from the phase 2 KEYNOTE-052 study
    Meeting Abstract

    Balar, A.; Bellmunt, J.; O'Donnell, P. H.; Castellano, D.; Grivas, P.; Vuky, J.; Powles, T.; Plimack, E. R.; Hahn, N. M.; de Wit, R.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save